MARC Record from Library of Congress

LEADER: 02153nam a22003377a 4500
001 2011926456
003 DLC
005 20111229152132.0
008 110330s2011 nyua b 001 0 eng d
010 $a 2011926456
020 $a9781617790942 (alk. paper)
020 $a161779094X (alk. paper)
020 $a9781617790959 (e-ISBN)
035 $a(OCoLC)ocn706626334
040 $aYDXCP$cYDXCP$dVGM$dSCB$dDLC
042 $alccopycat
050 00 $aRB155.8$b.V543 2011
245 00 $aViral vectors for gene therapy :$bmethods and protocols /$cedited by Otto-Wilhelm Merten, Mohamed Al-Rubeai.
260 $aNew York :$bHumana Press,$cc2011.
300 $axi, 450 p. :$bill. ;$c27 cm.
490 1 $aMethods in molecular biology ;$vv. 737
504 $aIncludes bibliographical references and index.
505 0 $aIntroduction to viral vectors -- Introduction to gene therapy: A clinical aftermath -- Host cells and cell banking -- Overview of current scalable methods for purification of viral vectors -- Methods to construct recombinant adenovirus vectors -- Manufacturing of adenovirus vectors: Production and purification of helper dependent adenovirus -- Manufacturing of retroviruses -- Lentiviral vectors -- Adeno-associated viruses -- Manufacturing of adeno-associated viruses, for example: AAV2 -- Vector characterization methods for quality control testing of recombinant adeno-associated viruses -- Baculoviruses mediate efficient gene expression in a wide range of vertebrate cells -- Herpes simplex virus type 1-derived recombinant and amplicon vectors -- Manufacture of measles viruses -- In vivo gene delivery into hCD34+ cells in a humanized mouse model -- In vivo evaluation of gene transfer into mesenchymal cells (in view of cartilage repair) -- Ethical consideration -- Clinical trials of GMP products in the gene therapy field.
650 0 $aGene therapy.
650 0 $aGenetic vectors.
650 0 $aTransfection.
650 0 $aViral genetics.
650 0 $aVirus-vector relationships.
700 1 $aMerten, Otto-Wilhelm.
700 1 $aAl-Rubeai, Mohamed,$d1948-
830 0 $aMethods in molecular biology (Clifton, N.J.) ;$vv. 737.